Trevi Therapeutics (TRVI) Other Accumulated Expenses (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Other Accumulated Expenses of $124000.0 for Q1 2026, up 44.19% year-over-year from $86000.0 in Q1 2025, and down 32.61% quarter-over-quarter from $184000.0 in Q4 2025.
Powered by 
Analysis
Trevi Therapeutics (TRVI) Other Accumulated Expenses (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $124000.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 44.19% year-over-year to $124000.0; the TTM figure through Mar 2026 stood at $124000.0 (up 44.19% YoY), while the FY2025 annual figure was $184000.0, up 327.91% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $124000.0, down from $184000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $498000.0 in Q4 2022, with the low at $6000.0 in Q4 2023.
- The 5-year median for Other Accumulated Expenses is $77000.0 (2022), against an average of $154882.4.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses sank 98.8% in 2023, then soared 616.67% in 2024.
- Trevi Therapeutics' Other Accumulated Expenses stood at $498000.0 in 2022, then tumbled by 98.8% to $6000.0 in 2023, then jumped by 616.67% to $43000.0 in 2024, then jumped by 327.91% to $184000.0 in 2025, then plunged by 32.61% to $124000.0 in 2026.
- Business Quant data shows TRVI's Other Accumulated Expenses at $124000.0 in Q1 2026, $184000.0 in Q4 2025, and $126000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Trevi Therapeutics | 2.71 Bn | 2.71 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 130,000.00 |
| Mar 31, 2026 | 124,000.00 |
| Dec 31, 2025 | 184,000.00 |
| Sep 30, 2025 | 126,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | 86,000.00 |
| Dec 31, 2024 | 43,000.00 |
| Sep 30, 2024 | 45,000.00 |
| Jun 30, 2024 | 35,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Jun 30, 2023 | 53,000.00 |
| Mar 31, 2023 | 467,000.00 |
| Dec 31, 2022 | 498,000.00 |
| Sep 30, 2022 | 415,000.00 |
| Jun 30, 2022 | 332,000.00 |
| Mar 31, 2022 | 77,000.00 |
| Dec 31, 2021 | 79,000.00 |
| Sep 30, 2021 | 70,000.00 |